ClinicalTrials.Veeva

Menu

Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study

K

Kasr El Aini Hospital

Status

Unknown

Conditions

Cardioplegia Solution Adverse Reaction

Treatments

Drug: Esmolol
Drug: Potassium Cardioplegic Solution

Study type

Interventional

Funder types

Other

Identifiers

NCT04306913
D-47-2019

Details and patient eligibility

About

Perioperative myocardial injury remains one of the most serious complications of cardiac surgery.

Numerous factors have been implicated during the pathogenesis process, including the technique of cardiac surgery, induction of cardioplegia and period of cardiac arrest.

Lactic acid is the normal endpoint of the anaerobic breakdown of glucose in the tissues. The lactate exits the cells and is transported to the liver, thus it's considered to be an indicator of ischemia as it is produced by most tissues in the human body, with the highest level of production found in muscle.

In any cardiac valve replacement surgery, patient must undergo cardiac bypass and arrest in diastole by using hyperkalemic cardioplegia solution; meanwhile the metabolism of myocardial cells is purely anaerobic.

Esmolol an ultra-short beta blocker is supposed to decrease the anaerobic insult to the myocardial cells.

Enrollment

80 estimated patients

Sex

All

Ages

20 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 20-50 years old patients, with either sex with solitary valvular disease

Exclusion criteria

  • • Myocardial infarction within 2 weeks.

    • History of reaction or toxicity to esmolol or other beta blockers.
    • New York Heart Association class IV congestive heart failure despite treatment.
    • Persistent hypotension (systolic blood pressure <80 mm Hg).
    • severe pulmonary hypertension
    • Ejection fraction less than 45%
    • Patients with coronary artery disease
    • Patients with congenital heart disease
    • Patients with previous cardiac surgery
    • Patients with liver disease (child class B and C)
    • Patients with second or third degree heart block
    • Patients having resting heart rate less than 50 ppm
    • Patients using calcium channel blockers

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups

Control
Active Comparator group
Treatment:
Drug: Potassium Cardioplegic Solution
Esmolol
Experimental group
Treatment:
Drug: Esmolol
Drug: Potassium Cardioplegic Solution

Trial contacts and locations

1

Loading...

Central trial contact

Ayman Abougabal, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems